Objective: The objective of this paper is to examine the role of place of residency in the expression and outcomes of systemic lupus erythematosus (SLE) in a multi-ethnic Latin American cohort. Patients and methods: SLE patients (<two years of diagnosis) from 34 centers constitute this cohort. Residency was dichotomized into rural and urban, cut-off: 10,000 inhabitants. Socio-demographic, clinical/laboratory and mortality rates were compared between them using descriptive tests. The influence of place of residency on disease activity at diagnosis and renal disease was examined by multivariable regression analyses. Results: Of 1426 patients, 122 (8.6%) were rural residents. Their median ages (onset, diagnosis) were 23.5 and 25.5 years; 85 (69.7%) patients were Mestizos, 28 (22.9%) Caucasians and 9 (7.4%) were African-Latin Americans. Rural residents were more frequently younger at diagnosis, Mestizo and uninsured; they also had fewer years of education and lower socioeconomic status, exhibited hypertension and renal disease more frequently, and had higher levels of disease activity at diagnosis; they used methotrexate, cyclophosphamide pulses and hemodialysis more frequently than urban patients. Disease activity over time, renal damage, overall damage and the proportion of deceased patients were comparable in rural and urban patients. In multivariable analyses, rural residency was associated with high levels of disease activity at diagnosis (OR 1.65, 95% CI 1.06-2.57) and renal disease occurrence (OR 1.77, 95% CI 1.00-3.11). Conclusions: Rural residency associates with Mestizo ethnicity, lower socioeconomic status and renal disease occurrence. It also plays a role in disease activity at diagnosis and kidney involvement but not on the other end-points examined.
Introduction
A number of population-based studies of systemic lupus erythematosus (SLE) have helped define the influence of ethnicity and other personal and social characteristics on the clinical expression and outcome of this disease. [1] [2] [3] [4] However, the influence of place of residence, i.e. rural vs. urban, has been only infrequently addressed and mostly in Caucasian populations. Major findings from these studies reveal the association of increased age at diagnosis, lower female to male ratio, around 5:1 compared to typical 9:1, but similar clinical features regarding disease severity and mortality in patients from rural settings as compared to those from urban areas. 5, 6 In addition, some data suggest that rural populations experience poorer clinical outcomes probably related to their low socioeconomic status, educational levels and inadequate access to health care. 7, 8 A major disadvantage for SLE patients living in rural areas is the limited availability of providers with adequate levels of expertise to care for them appropriately. It is well documented that SLE mortality is lower in large referral hospitals with experience in treating these patients and that end-stage renal disease in SLE occurs more frequently in populations with limited hospital access. [9] [10] [11] Today the boundaries between rural and urban residential areas in developed countries have been affected by globalization, which brings improvements in communication and transportation systems. In Latin America, like in other parts of the world, however, there are still highly distinct geographical areas where the differences between rural and urban settings are quite noticeable. We hypothesized that lupus patients living in rural areas will experience less favorable disease outcomes not only because of more severe disease but because of the modulating effects of poverty, limited health care access and possibly some environmental factors. We have examined such a hypothesis using data from a large multi-ethnic Latin American lupus cohort, the Grupo Latino Americano De Estudio del Lupus (GLADEL), or the Latin American Group for the Study of Lupus.
Patients and methods

Patients
Patients were those participating in GLADEL, a multinational, inception longitudinal cohort study composed of Latin American centers having experience in the diagnosis and management of SLE and aimed at determining the different socioeconomic-demographic, clinical, genetic and treatment characteristics in the course and outcome of SLE patients from the region [Mestizos (mixed Caucasian and Amerindian ancestry), Caucasians and African-Latin American].
As previously described, 12 the GLADEL cohort comprises 34 centers distributed among nine Latin American countries, each following a common protocol with consensus definitions and outcome measures. Institutional review boards' local regulations were followed at all centers. All data were collected into the ARTHROS database (a userfriendly database developed by Argentinean rheumatologists using a Windows platform, Visual Basic language and Microsoft Access). Data were submitted via the Internet to the coordinating center, where they were reviewed to ensure their quality.
For all patients the diagnosis of SLE was made by a rheumatologist or a qualified internist with experience in SLE based on the clinical and laboratory features present. Fulfillment of four American College of Rheumatology (ACR) SLE criteria 13, 14 at the time of diagnosis was not mandatory. For this cohort all clinical (related and un-related to SLE), laboratory and therapeutic features were evaluated at disease onset and during its course (cumulative incidence). Socioeconomic status was defined as per the Graffar scale that takes into account the following five variables: parents' occupation, parents' level of education, main source of income, housing and neighborhood quality. 15 Autoantibodies and complement tests were performed with cutoff values considered to be valid at each center. The activity index [Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)] 16 was assessed at the time of entry and then twice a year, whereas the damage index (Systemic Lupus International Collaborating Clinics/ACR Damage Index (SLICC/ACR or SDI) 17 was ascertained at entry and yearly thereafter. Exposure to medications was dichotomized according to their use (users and non-users).
The variable of interest, place of residency, was dichotomized into rural (<10,000 inhabitants) and urban (10,000 inhabitants). End-points were renal disease occurrence, disease activity (diagnosis and over time), renal damage and damage overall, and mortality; renal disease was defined by the respective ACR renal criterion (persistent proteinuria and/ or cellular casts); high disease activity was defined as a SLEDAI >11; renal damage and damage overall were defined as per the SDI/ACR index.
Statistical analyses
All variables described above were examined as a function of the place of residency using descriptive statistical tests, Wilcoxon's, Chi-square and Kruskal Wallis tests as appropriate for continuous and categorical variables, respectively. Additionally, multivariable logistic regression models were performed to evaluate the influence of place of residency in disease activity at diagnosis and renal involvement. All results are presented as odds ratios (OR) with their corresponding 95% confidence intervals (CIs). Analyses were performed using either SAS, version 9.1 (SAS Institute, Cary, NC, USA) or SPSS, version 15.0 (Chicago, IL, USA).
Results
One hundred and twenty-two (8.6%) out of 1426 SLE Latin American patients who constitute the GLADEL cohort were identified as living in rural areas. Of them, 107 (87.7%) were women, their median (Q3-Q1 interquartile range) age at disease onset and age at diagnosis were 23.5 (Q3-Q1: 17.0-32.0) and 25.5 (Q3-Q1: 18.0-34.0) years, respectively; their median disease duration was 54.2 months (Q3-Q1: 29.9-72.9). Fifty-one (41.8%) were without medical insurance, 111 (91.0%) had 12 or less years of formal education and 100 (82.0%) had a low socioeconomic status. Eightyfive (69.7%) of the patients living in rural areas were Mestizos, 28 (22.9%) were Caucasians and 9 (7.4%) were African-Latin Americans. Table 1 depicts the features of GLADEL SLE patients as a function of place of residency. The proportion of Mestizos was higher among rural patients; conversely, there were more Caucasians and African-Latin American patients living in urban areas. Rural patients were also younger at diagnosis, while urban patients showed a higher number of years of formal education, better socioeconomic status and medical coverage than those living in rural areas. Within the clinical features, urban patients presented more frequently with myalgias/myositis while a comorbid condition such as hypertension and renal disorders were more frequent among patients in the rural areas. Disease activity at diagnosis was significantly higher in rural patients but not over time. Renal damage and overall damage were comparable in both groups. As for the treatment variables, the use of methotrexate, cyclophosphamide pulses and the need for hemodialysis were found to be more common in the rural patients. A numerically higher proportion of deaths occurred during follow-up among the rural patients but the difference with the urban patients was not statistically significant. When these features were examined as a function of ethnicity, some differences were also observed, as noted in Table 2 . For example, discoid lupus and pericarditis were more frequent among the African-Latin Americans, while hematological and renal manifestations were more common among Mestizo and African-Latin American patients in comparison to the Caucasian patients. Disease activity at diagnosis was also higher in the patient groups in whom a higher proportion had acquired some renal damage and overall damage. Finally, the use of medications was not uniform across the groups; for example, African-Latin Americans tended to use higher corticosteroid doses than patients in the other two groups while a higher proportion of non-Caucasians had received pulses of cyclophosphamide, and a higher proportion of Mestizos had received methotrexate. 
Univariable analyses
Impact of place of residence on disease activity and renal disease
After adjusting for possible confounding factors using multivariable logistic regression models, we found that rural residency was statistically associated with high disease activity (SLEDAI>11) at diagnosis (OR 1.65, 95% CI 1.06-2.57) and with the occurrence of renal disease over time (OR 1.77, 95% CI 1.00-3.11) as shown in Tables 3  and 4 , respectively.
Discussion
In this study, we have examined the role of place of residency on the expression and outcome of SLE in the largest multi-national Latin American cohort: GLADEL. Patients residing in rural areas were more likely to be Mestizo, to have lower socioeconomic status, educational level and medical insurance coverage and to experience more active disease at diagnosis, renal disease occurrence over time (not previously reported) but not worse outcomes in terms of disease activity over time, renal damage, overall damage and mortality. Socioeconomic factors have been recognized as important mediators of less favorable outcomes in patients from GLADEL 12 as well as in patients studied by others, [18] [19] [20] suggesting that, in fact, these factors may play a more important role than place of residency per se in terms of their impact on the intermediate (disease activity, renal and overall damage) and final outcomes (mortality) of this disease. However, even after adjusting for the socioeconomic parameters examined, place of residency had an important impact on terms of disease activity at diagnosis and the occurrence of renal disease over the disease course. These data may reflect the fact that rural residents in Latin America may not have the same access to specialized care, being more frequently cared for by family or primary care physicians, nurse practitioners and physician assistants; in addition, social services may be less available to these patients; the end result is that they may present to the rheumatologists only when the disease is quite evident and active. This has been clearly shown by Ward, who found that SLE patients with limited access to care, perhaps a subrogate variable for place of residency, were more likely to develop end-stage renal disease; 21 however, we could not demonstrate that patients in the rural areas experienced a significant lag time in presenting to a health care provider as compared to those living in urban settings. Place of residency may also reflect environmental exposures that may trigger or influence different patterns of disease expression in SLE. While factors such as work-related increase in the levels of sunlight, 22, 23 pesticides, herbicides and other exposures 23, 24 are more likely to occur in rural areas of Latin-America, others, like air pollutant levels, 25 may be found more frequently in urban areas. Finally, other factors such as smoking, 23, 26 higher rates of infections highly associated with lupus such as Epstein Barr virus 27, 28 and rubella 29 may be observed equally in urban and rural areas. Given the fact that our cohort includes patients from different geographic areas and ecological systems of Latin America, it is hard to hypothesize that a single possible exposure could have triggered the onset of this disease or the occurrence of renal disease among rural residents. We must note, however, that environmental exposures were not explored in our study.
The fact that we did not find differences in the rates of hospitalization, and in intermediate (disease activity over the disease course, renal damage and damage overall) and long-term outcomes (mortality) may actually reflect the fact that once patients enter the health system, their course is somewhat comparable to that of patients living in urban areas. This is a likely explanation for patients in the GLADEL cohort given that once they are diagnosed they are followed and treated by either rheumatologists or internists with a great degree of experience in the management of SLE. In addition, it is possible that after their enrollment in the cohort these patients may have become proactive in their care, seeking help when their disease was active, which may have resulted in avoidable hospitalizations as hypothesized by Ward. 30 The clear strengths of our study include the large number of patients studied, the multiethnic and multinational composition of the cohort, including patients living in rural places all around Latin America. From this vantage point, we have dealt with the effect of a variable infrequently assessed in other studies. The primary limitation of our study is that we were unable to include in our analyses data on environmental exposures and access to care (time to appointment and travel distance) since this information had not been obtained; however, place of residency may be a surrogate measure for these later variables in multivariable models.
This study offers a clear picture of the significant socioeconomic-demographic, clinical, serologic and treatment differences present in SLE patients living in urban and rural settings in Latin America. The data presented are important if the care of SLE patients living in rural areas is to improve; thus, it behooves us to keep health authorities in our respective countries informed of our findings so adequate remedial strategies may be implemented. Likewise, physicians working in rural areas (commonly primary care physicians) should be aware of this condition and make every effort to identify patients afflicted with it early enough so that they can be promptly referred to specialists not only for confirmation of their diagnosis but for the implementation of treatment strategies and establishment of an adequate follow-up plan.
